Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.69 USD | +0.15% | -2.80% | -17.68% |
Jul. 01 | HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study | MT |
Jul. 01 | HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.68% | 83.09B | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 10